Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927287 | 0.90 | ALOX15 (0.81) | ALOX15MEN1KMT2APOLBCYP1A2 | |
| SCHEMBL5926986 | 0.86 | ALOX15 (0.75) | ALOX15MEN1KMT2APOLBMAPT | |
| SCHEMBL11142679 | 0.85 | ALOX15 (0.73) | ALOX15KMT2ABRD4POLBCYP1A2 | |
| SCHEMBL5926887 | 0.83 | ALOX15 (0.71) | ALOX15MEN1KMT2AAOC3LMNA | |
| SCHEMBL5926876 | 0.83 | ALOX15 (0.71) | ALOX15POLBNPSR1L3MBTL1 | |
| SCHEMBL5926897 | 0.82 | ALOX15 (0.70) | ALOX15MEN1KMT2APOLBLMNA | |
| SCHEMBL5926896 | 0.81 | ALOX15 (0.68) | ALOX15MEN1KMT2APOLBSLC6A4 | |
| SCHEMBL5926758 | 0.80 | ALOX15 (0.67) | ALOX15SMN1; SMN2 | |
| SCHEMBL6552275 | 0.79 | ALOX15 (0.66) | ALOX15MEN1KMT2AADRB2BRD4 | |
| SCHEMBL5926734 | 0.79 | ALOX15 (0.65) | ALOX15IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | claimed |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-06 | — | — | US | claimed |
| CN-107902464-B | Tension swing rod device | 上海智联精工机械有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-11845824-B2 | Same novel polymer and organic light emitting device comprising the same | LG CHEM, LTD. | 2023-12-19 | — | — | US | claimed |
| WO-2023144357-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | UNIVERSITE PARIS CITE (FR) | 2023-08-03 | — | — | WO | claimed |
| EP-4048399-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | claimed |
| EP-4048659-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2022-08-31 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060009423-A1 | Phosphonate-phosphate and diphosphonate apolipoprotein e modulators | NIESOR ERIC JOSEPH | 2006-01-12 | — | — | US | claimed |
| EP-1485106-A2 | PHOSPHONATE-PHOSPHATE AND DIPHOSPHONATE APOLIPOPROTEIN E MODULATORS | Ilex Products, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003070179-A2 | PHOSPHONATE-PHOSPHATE AND DIPHOSPHONATE APOLIPOPROTEIN E MODULATORS | ILEX PRODUCTS, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-4416877-A | Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds | SYMPHAR S.A. (CH) | 1983-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009423-A1 | Phosphonate-phosphate and diphosphonate apolipoprotein e modulators | APOB, PHOSPHO1, ENPP2 | ALOX15 809/4885MEN1 3169/4885KMT2A 4268/4885 |
| US-20240182445-A1 | MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | ALOX15 2756/4885MEN1 2848/4885KMT2A 3385/4885 |
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | ALOX15 3088/4885MEN1 2570/4885KMT2A 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.